NitroMed About
NitroMed NitroMed® is an emerging pharmaceutical company focused
on the research, development and commercialization of proprietary pharmaceuticals
based on the therapeutic benefits of the naturally occurring molecule nitric oxide.
The goal is to become a leading, multi- product pharmaceutical company by developing
innovative nitric oxide products The Company is currently developing a
lead nitric oxide-enhancing drug candidate, BiDil, to treat African Americans
diagnosed with heart
failure.
NitroMed is also applying nitric oxide technology with the goal of developing
new pharmaceuticals, as well as safer and more effective versions of existing
drugs. The research and development efforts focus on major diseases that are characterized
by a deficiency in nitric oxide, such as cardiovascular and inflammatory diseases.
BiDil -- Heart
failure, or end-stage cardiovascular disease More
Info on NitroMed